The inspection by the USFDA was conducted from 30 May 2023 to 2 June 2023.
Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The company's consolidated net profit (from continuing operations) tumbled 27.55% to Rs 298.8 crore despite of 31.66% jump in total revenue from operations to Rs 5,010.6 crore in Q4 FY23 over Q4 FY22.
The scrip rose 1.01% to end at Rs 518.55 on Friday, 2 June 2023.
|